【摘要】 目的观察伊立替康(CPT-11商品名艾力)联合氟尿嘧啶(5-Fu)与四氢叶酸(CF)治疗晚期胃癌的疗效与毒性作用。方法对我中心2008年10月至2011年4月对26例采用该方案治疗的晚期胃癌患者进行回顾性分析。用法:CPT-11 180mg/m2,静脉滴注30～90min,第1d;CF 400mg/m2,静脉滴注2h,第1d;5-Fu400mg/m2,继CF后静脉滴注,然后2400 mg/m24,6h,第1d,14d为1个周期,每3～4个周期后按照RECIST实体瘤近期客观疗效评定标准进行疗效评价。结果 CR 1例,PR 10例,SD 7例,PD 8例。临床获益率(CR+PR+SD)69.2%。疾病稳定期5.9个月,中位生存期10.1个月。主要不良反应为恶心呕吐骨髓抑制腹泻,肝功能异常口腔黏膜炎等发生率低,未观察到肾毒性和心脏毒性,无化疗相关死亡病例。结论伊立替康联合氟尿嘧啶与四氢叶酸治疗晚期胃癌疗效较好,不良反应可耐受,适合该类患者使用。更多还原

【Abstract】 Objective To observe the efficacy and safety of FOLFIRI regimen in first-line treatment of patients with advanced gastric cancer.Methods Twenty-six patients with advanced gastric cancer treated with FOLFIRI regimen from October 2008 to April 2011 were reviewed and analyzed.The regimen included irinotecon(CPT-11) 180 mg/m2 d1,iv dripping in 30~90 minutes;Leucovorin(CF) 400 mg/m2 iv infusion over 2 hours on day 1;Fluorouracil 400 mg/m2 iv bolus on day one,then 2400 mg/m2 iv infusion over 46 hours.The regimen was repeated every 14 days.The patients were assessed on the basis of Response Evaluation Criteria in Solid Tumors(RECIST) after 3~4 cycles.Results Twenty-six patients were assessable for the efficacy and safety.Of them,1 had complete response;10 had partial response;7 had stable disease and 8 had progression disease.The clinical tumor control rate was 69.2%(18 /26).Median time to progression(TTP) was 5.9 months and median survival time(MST) was 10.1 months.The main toxic reactions were nausea,vomiting,myelosuppression and tardive diarrhoea.Conclusions FOLFIRI regimen is effective and well tolerable in the-first-line treatment for advanced gastric cancer,and is worth of use.更多还原